Tarenflurbil

Drug Profile

Tarenflurbil

Alternative Names: R-Flurbiprofen; E-7869; Flurizan; MPC-7869; TMP-001; TruNoc

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Loma Linda University Medical Center
  • Developer Fraunhofer Institute for Molecular Biology and Applied Ecology; Horizon Pharma AG; Myriad Pharmaceuticals
  • Class Antidementias; Antineoplastics; Biphenyl compounds; Propionic acids; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators; NF-kappa B inhibitors; Transcription factor AP-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Discontinued Alzheimer's disease; Inflammation; Pain; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 16 Jul 2015 Phase-II clinical trials in Multiple sclerosis (Relapsing, remitting) in Germany (PO) (EudraCT2014-004483-38)
  • 23 Mar 2012 Discontinued - Preclinical for Inflammation in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top